Submodule
Phenotype, Severity, and Differential
Rhinitis describes congestion, rhinorrhea, sneezing, itching, or postnasal symptoms. The same complaint can arise from IgE allergy, neural hyperreactivity, infection, medicines, anatomy, inflammation, or a dangerous alternate process.
- Allergic pattern
- Intermittent and persistent burden
- Nonallergic rhinitis
- Structural disease
- Diagnostic red flags
Relevant allergen exposure and IgE
Weather, odor, food, hormones, medicine
Sinus, septum, polyp, leak, foreign body, mass
Recognize the allergic pattern
Allergic rhinitis commonly produces sneezing, nasal itching, clear rhinorrhea, congestion, and ocular itching or tearing after relevant exposure. Seasonal and perennial labels describe exposure patterns, while intermittent or persistent and mild or moderate-to-severe categories better express frequency and impact.
Differentiate nonallergic phenotypes
Temperature change, odors, smoke, eating, hormonal change, exercise, medications, or no clear trigger can produce nonallergic rhinitis. Prominent watery rhinorrhea without itching may favor a cholinergic phenotype. Mixed rhinitis is common, so one patient can have both IgE and nonallergic mechanisms.
Look for infection and structure
Purulent discharge alone does not prove bacterial sinusitis. Duration, severe onset, double worsening, facial pain, fever, smell loss, dental source, and examination matter. Septal deviation, turbinate hypertrophy, polyps, adenoids, foreign body, cerebrospinal fluid leak, and neoplasm require targeted evaluation rather than repeated allergy escalation.
Treat red flags as a different pathway
Unilateral persistent obstruction or bleeding, orbital signs, severe headache, neurologic findings, clear unilateral fluid after trauma, recurrent severe epistaxis, neck mass, or systemic illness warrants prompt focused assessment. Asthma symptoms, sleep disruption, otitis, and occupational exposure also change urgency and scope.
Quick check
Submodule
Immunology, Testing, and Comorbidity
Sensitization becomes disease only when allergen-specific IgE and exposure align with symptoms. Testing confirms a clinically relevant hypothesis rather than replacing history.
- Sensitization
- Early and late response
- Skin testing
- Serum specific IgE
- Asthma and conjunctivitis
B-cell class switching and mast-cell loading
Histamine drives rapid itch, sneeze, and rhinorrhea
Cell recruitment sustains congestion and hyperreactivity
Follow the allergic cascade
Allergen cross-links specific IgE on mast cells, releasing histamine and other mediators that cause rapid itching, sneezing, and rhinorrhea. Cytokines and recruited inflammatory cells support a later response with persistent congestion and hyperreactivity. Different treatments act at different points in this cascade.
Separate sensitization from clinical allergy
A positive skin test or serum specific IgE shows sensitization, not necessarily the cause of symptoms. Match allergen, exposure timing, geography, indoor environment, occupation, pets, season, and response. Broad panels increase irrelevant positives and confusion.
Select the testing method
Skin-prick testing is sensitive, provides immediate results, and supports allergen selection when medicines and skin condition permit. Serum specific IgE is useful when antihistamines cannot be stopped, skin disease is extensive, or testing risk or access favors blood testing. Total IgE and food panels do not routinely diagnose rhinitis.
Assess the united airway
Allergic rhinitis frequently coexists with conjunctivitis and asthma and can impair sleep, school, work, and exercise. Ask about wheeze, cough, chest tightness, night symptoms, inhaler use, ocular symptoms, eczema, sinus disease, sleep-disordered breathing, and oral allergy syndrome.
Quick check
Submodule
Exposure Control, Irrigation, and Technique
Targeted exposure reduction and correct nasal delivery can change treatment more than adding another medication. Advice should be relevant, feasible, and verified.
- Allergen-specific control
- Saline irrigation
- Spray positioning
- Adherence
- Trigger and environment plan
Correct product setup and a gently cleared nose
Neutral head and lateral nozzle direction
Observe use, adherence, tolerability, and response
Target the exposure that matters
Use testing and history to prioritize interventions. Dust-mite encasements, humidity control, pest management, mold remediation, pet decisions, pollen timing, occupational controls, smoke avoidance, and ventilation vary in feasibility and evidence. Multicomponent plans are more credible than one symbolic measure.
Use saline safely
Saline irrigation can improve symptoms and reduce mucus or allergen burden. Use distilled, sterile, previously boiled and cooled, or otherwise appropriately filtered water, clean the device, and prepare the correct saline concentration. Contaminated tap water and poor device hygiene create avoidable risk.
Aim away from the septum
Gently clear the nose, prime and shake as directed, keep the head neutral or slightly forward, use the opposite hand when helpful, aim laterally toward the ear, inhale gently, and avoid a forceful sniff into the throat. Septal spraying increases irritation and bleeding.
Diagnose apparent treatment failure
Verify that the product was obtained, used daily when required, primed, positioned, and continued long enough. Review taste, dryness, epistaxis, sedation, cost, fear, literacy, dexterity, and expectations. Reassess phenotype, exposure, anatomy, and asthma before escalating.
Quick check
Submodule
Stepwise Pharmacotherapy
Intranasal therapy provides the strongest overall nasal control. Selection balances burden, symptom domain, onset, adherence, adverse effects, age, pregnancy, access, and preference.
- Intranasal corticosteroid
- Intranasal antihistamine
- Fixed combination
- Oral antihistamine
- Adjuncts and limits
Broad anti-inflammatory symptom control
Rapid local H1 blockade across phenotypes
Greater and faster control when monotherapy is insufficient
Use intranasal corticosteroids as a foundation
Intranasal corticosteroids provide broad control of congestion, rhinorrhea, sneezing, and itching and are preferred over oral antihistamines for persistent or more burdensome disease. Benefit improves with consistent use and correct technique. Local dryness and epistaxis are reduced by lateral aim and dose adjustment.
Use intranasal antihistamines for speed and breadth
Intranasal antihistamines act quickly and can help allergic and nonallergic rhinitis. Bitter taste and local irritation affect adherence. ARIA-EAACI recommends intranasal antihistamine over no treatment and supports either intranasal or oral second-generation antihistamine according to efficacy, acceptance, cost, and adverse effects.
Escalate to a fixed nasal combination
A fixed intranasal antihistamine plus corticosteroid provides faster and often greater symptom control than either component alone and is favored when monotherapy is unlikely to be enough or has failed. Confirm technique and adherence first, and account for cost, taste, age-specific labeling, and preference.
Use adjuncts for a defined symptom
Second-generation oral antihistamines can help itching and sneezing and are safer than first-generation agents. Intranasal ipratropium targets prominent watery rhinorrhea. Ocular antihistamine drops target eye symptoms. Topical decongestants should be very short term, preferably fewer than five days, to avoid rebound. Montelukast is reserved for inadequate response or intolerance to alternatives because of limited comparative benefit and serious neuropsychiatric warning.
Quick check
Submodule
Safety, Special Populations, and Refractory Disease
Children, pregnancy, older adults, glaucoma, epistaxis, occupational disease, and coexisting asthma change the benefit-risk discussion. Refractory symptoms require diagnostic review, not automatic systemic therapy.
- Children
- Pregnancy and lactation
- Older adults
- Medication safety
- Specialist referral
Growth, school, work, pregnancy, falls
Bleeding, sedation, pressure, retention, interactions
Asthma, polyps, structure, unilateral signs, occupational disease
Protect learning and development
In children, assess sleep, behavior, school performance, growth, asthma, adenoids, otitis, and technique. Avoid sedating first-generation antihistamines when safer options exist. Use the lowest effective intranasal corticosteroid dose within age-specific labeling and monitor growth in prolonged treatment.
Individualize pregnancy and lactation
Begin with exposure control and saline when sufficient, then choose medications with established experience and the lowest effective exposure. Budesonide has extensive pregnancy experience, while current ARIA guidance applies intranasal corticosteroid preference broadly but notes concern about triamcinolone pregnancy data. Coordinate uncontrolled asthma and rhinitis care.
Reduce anticholinergic and sedative harm
First-generation antihistamines impair vigilance, driving, learning, and fall risk and add anticholinergic burden. Oral decongestants can worsen pressure, tachycardia, urinary retention, insomnia, and anxiety. Review glaucoma, prostate disease, cardiovascular disease, cognition, occupation, and interacting sedatives.
Refer when the pathway no longer fits
Refer for uncertain diagnosis, refractory symptoms despite verified treatment, severe epistaxis, polyps, recurrent sinus disease, unilateral findings, suspected occupational allergy, asthma instability, candidate immunotherapy, or need for endoscopy, imaging, surgery, or allergen challenge.
Quick check
Submodule
Allergen Immunotherapy
Allergen immunotherapy modifies disease through repeated controlled exposure. It requires confirmed clinical relevance, a product-specific protocol, adherence, and preparation for systemic reactions.
- Candidate selection
- SCIT
- SLIT
- Anaphylaxis readiness
- Long-term disease modification
Test, exposure, and symptom pattern agree
Setting, protocol, adherence, and patient goals
Asthma control, epinephrine, observation, education
Select a clinically relevant allergen
Consider immunotherapy when symptoms remain important despite avoidance and pharmacotherapy, adverse effects or preference limit medicines, or long-term disease modification is desired. Sensitization must match exposure and symptoms. Treating irrelevant positive tests adds cost and risk.
Compare SCIT and SLIT
Subcutaneous immunotherapy can address selected allergen extracts through clinic-administered buildup and maintenance but carries systemic reaction risk. FDA-approved sublingual tablets are allergen-specific, use a first supervised dose, and continue daily at home. They are not interchangeable with unapproved liquid mixtures.
Control asthma before dosing
Uncontrolled or severe asthma increases the risk of serious immunotherapy reactions. Assess current symptoms and respiratory status before injections or supervised tablet initiation, review beta-blockers and other risk modifiers, and defer dosing during significant instability according to protocol.
Prepare for anaphylaxis and adherence
Observe after SCIT according to clinic protocol and ensure trained staff, epinephrine, and emergency response are available. SLIT tablet users need epinephrine and education about oral symptoms, systemic reactions, missed doses, and when to stop or contact the prescriber. Benefits depend on sustained multi-year adherence.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.